Kazia Therapeutics (KZIA) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Kazia Therapeutics presented promising data from a Phase 1 trial of EVT801, showing potential as a first-in-class VEGFR-3 inhibitor for treating high-grade serous ovarian cancer. The study identified a well-tolerated maximum dose and demonstrated encouraging signs of clinical activity, including a partial response in one patient and stable disease in 46% of participants. The company’s presentation at the 15th Biennial Ovarian Cancer Research Symposium has generated optimism for future developments in ovarian cancer therapy.
For further insights into KZIA stock, check out TipRanks’ Stock Analysis page.
